1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
65,247
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing and Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
33,446
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
16,216
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities further to the vesting of
awards granted in 2015 under the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$37.4803
|
14,389
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
26,605
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
35,473
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
20,524
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D E Troy
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities further to the vesting of
awards granted in 2015 under the Company's 2009 Performance Share
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$37.4803
|
31,635
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President, R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
73,783
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs V A Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
4,544
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-16
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
20, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|